Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

77 citing papers in PubMed, 5 syntheses or guidelines pooled it.

1. Immune-related adverse events with cancer clinical benefits: a systematic review and meta-analysis.BMC cancer · 2026
   Pooled it
2. Concomitant anticoagulants and the survival of cancer patients treated with immune checkpoint inhibitors: a meta-analysis.Scientific reports · 2025
   Pooled it
3. Prognostic value of platelet-to-lymphocyte ratio in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.BMC gastroenterology · 2025
   Pooled it
4. Efficacy and safety of pembrolizumab in the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis.European journal of clinical pharmacology · 2025
   Pooled it
5. Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis.Frontiers in immunology · 2025
   Pooled it
6. Immunotherapy impact of macrophage glycosylation on cholangiocarcinoma and its prognostic and immune microenvironment significance.Human vaccines & immunotherapeutics · 2026
   Article
7. NAT10 promotes proliferation, invasion, and epithelial-mesenchymal transition in hepatocellular carcinoma through α-tubulin acetylation.Cell adhesion & migration · 2026
   Article
8. Aberrant sialylation in cancer: From molecular mechanisms to potential therapeutics.Genes & diseases · 2026
   Review
9. Mechanistic study of LINC00839-mediated suppression of anoikis in hepatocellular carcinoma via regulation of FOXM1.Translational oncology · 2026
   Article
10. Safety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study.Cancer pathogenesis and therapy · 2026
    Article
11. Pharmacokinetics and anti-tumor efficacy of transarterial chemoembolization using small-particle lenvatinib-loaded beads in a rabbit VX2 liver tumor model.Quantitative imaging in medicine and surgery · 2026
    Article
12. Efficacy and safety comparisons of PD-1 versus PD-L1 inhibitors in patients with solid cancer: a systematic review and meta-analysis.Journal of the National Cancer Center · 2026
    Article
13. PD-1/PD-L1 expression and predictive value of efficacy in hepatocellular carcinoma patients with anti-PD-1 therapy: a real-world study.Journal of gastrointestinal oncology · 2026
    Article
14. Journal of gastrointestinal oncology · 2026
    Article
15. Influence of Gut Microbiota on Response to Immune Check Point Inhibitors in MASLD Patients With HCC: Unraveling the Connection.Cancer medicine · 2026
    Review
16. Surgical treatment of extrahepatic intraabdominal hydatid cysts: A single-centre retrospective analysis.Experimental and therapeutic medicine · 2026
    Article
17. Role of cuproptosis in digestive system tumors (Review).International journal of molecular medicine · 2026
    Review
18. Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes.Journal of gastrointestinal oncology · 2026
    Article
19. Integrated spatial and single-cell transcriptomics reveals RPL8 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma.Translational oncology · 2026
    Article
20. Exercise amounts, barriers, and preferences among patients with cancer.Medicine · 2026
    Observational

17 more citing papers are in PubMed but not listed here.

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as